Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MYRIAD GENETICS INC
Report date May 14, 2021 · Filed May 28, 2021
Section 16 reporting ended · disclosed 2021-05-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,407 |
Reported balance
Holding disclosure · report date 2021-05-14 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 87,407 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 24, 2021 Filed Mar 26, 2021 20:37 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 10,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001826133-21-000004 · edgardoc.xml · nonDerivative · entry 1 Parkinson Paul · CIK 0001826133 · EVP Strategy and Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,407 F1 · kind: Consists of time-based restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 08, 2021 Filed Jan 11, 2021 21:40 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | SaleCommon Stock | 11,824 | $25.00 | $295,600.00 |
DisclosureSEC source: 0001826133-21-000002 · edgardoc.xml · nonDerivative · entry 1 Parkinson Paul · CIK 0001826133 · EVP Strategy and Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,746 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| October 31, 2020 Filed Nov 3, 2020 02:22 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,218 | $12.43 | $27,569.74 |
DisclosureSEC source: 0001826133-20-000009 · edgardoc.xml · nonDerivative · entry 1 Parkinson Paul · CIK 0001826133 · EVP Strategy and Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,570 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| October 08, 2020 Filed Oct 13, 2020 12:19 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 21,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001826133-20-000007 · edgardoc.xml · nonDerivative · entry 1 Parkinson Paul · CIK 0001826133 · EVP Strategy and Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,788 F1 · kind: Consists of restricted stock units granted pursuant to the Company's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock and vests 25% on October 9, 2021, 25% on October 9, 2022, 25% on October 9, 2023, and 25% on October 9, 2024. Read SEC document |
| September 26, 2020 Filed Sep 28, 2020 17:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 3,327 | $12.44 | $41,387.88 |
DisclosureSEC source: 0001826133-20-000005 · edgardoc.xml · nonDerivative · entry 3 Parkinson Paul · CIK 0001826133 · EVP Strategy and Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,058 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,218 | $12.44 | $27,591.92 |
DisclosureSEC source: 0001826133-20-000005 · edgardoc.xml · nonDerivative · entry 2 Parkinson Paul · CIK 0001826133 · EVP Strategy and Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,385 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
| September 25, 2020 Filed Sep 28, 2020 17:10 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | Disposition to issuerCommon Stock | 2,218 | $12.44 | $27,591.92 |
DisclosureSEC source: 0001826133-20-000005 · edgardoc.xml · nonDerivative · entry 1 Parkinson Paul · CIK 0001826133 · EVP Strategy and Innovation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,603 F1 · kind: Represents shares withheld by the Company to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.